J0737Inj, clindamycin (baxter)
Published CMS Medicare Part B payment-limit context for J0737, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$2.186
per 300 MG · Medicare Part B
Down 5.9%from $2.324 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$2.9687$1.5633
2024-Q4: $2.815; 2025-Q1: $2.605; 2025-Q2: $2.527; 2025-Q3: $1.717; 2025-Q4: $2.208; 2026-Q1: $2.346; 2026-Q2: $2.324; 2026-Q3: $2.186
Ingredient appears in FDA shortage dataFDA’s latest completed shortage data includes an affected record matching the Clindamycin Phosphate ingredient family (FDA data as of August 20, 2026).
Clindamycin Phosphate
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Other Clindamycin Phosphate presentations
1 other CMS codeSource-linked same ingredient-family context, not recommendations, substitutes, or clinical or billing equivalence.
Swipe to see all columns
| HCPCS | CMS description | Current quarter 2026-Q3 | Prior quarter 2026-Q2 | Change | NDCs | View history |
|---|---|---|---|---|---|---|
| J0736 | Inj, clindamycin phosp 300mg | $1.974 per 300 MG | $1.855 per 300 MG | Up 6.4% |
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.